Ifrah Financial Services Inc. lowered its stake in USANA Health Sciences, Inc. (NYSE:USNA) by 14.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,039 shares of the company’s stock after selling 697 shares during the quarter. Ifrah Financial Services Inc.’s holdings in USANA Health Sciences were worth $276,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in USANA Health Sciences by 72.6% in the 2nd quarter. BlackRock Inc. now owns 2,302,511 shares of the company’s stock valued at $182,889,000 after purchasing an additional 968,239 shares during the period. Nuveen Asset Management LLC acquired a new stake in USANA Health Sciences in the 2nd quarter valued at $17,458,000. Schroder Investment Management Group grew its position in USANA Health Sciences by 183.1% in the 2nd quarter. Schroder Investment Management Group now owns 212,492 shares of the company’s stock valued at $16,878,000 after purchasing an additional 137,430 shares during the period. Wasatch Advisors Inc. grew its position in USANA Health Sciences by 127.0% in the 2nd quarter. Wasatch Advisors Inc. now owns 96,447 shares of the company’s stock valued at $7,661,000 after purchasing an additional 53,960 shares during the period. Finally, State of New Jersey Common Pension Fund D acquired a new stake in USANA Health Sciences in the 3rd quarter valued at $2,633,000. Institutional investors own 63.53% of the company’s stock.
Several analysts recently issued reports on the stock. ValuEngine raised shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Jefferies Financial Group started coverage on shares of USANA Health Sciences in a research report on Thursday, August 22nd. They issued a “hold” rating and a $65.00 price target for the company. Pivotal Research reaffirmed a “buy” rating on shares of USANA Health Sciences in a report on Wednesday, July 24th. Finally, Zacks Investment Research raised shares of USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $86.00 price objective on the stock in a report on Saturday, October 26th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $74.00.
In other news, CFO G Doug Iiekking sold 1,746 shares of USANA Health Sciences stock in a transaction on Friday, October 25th. The stock was sold at an average price of $75.33, for a total transaction of $131,526.18. Following the sale, the chief financial officer now directly owns 2,032 shares in the company, valued at approximately $153,070.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joshua Foukas sold 1,115 shares of USANA Health Sciences stock in a transaction on Monday, October 28th. The stock was sold at an average price of $74.53, for a total value of $83,100.95. The disclosure for this sale can be found here. Insiders have sold a total of 8,385 shares of company stock worth $617,279 over the last ninety days. Insiders own 42.50% of the company’s stock.
USNA traded up $0.53 during mid-day trading on Friday, reaching $75.81. 65,162 shares of the stock were exchanged, compared to its average volume of 241,363. The stock has a market capitalization of $1.68 billion, a PE ratio of 14.69 and a beta of 0.28. The company has a 50 day moving average price of $71.01 and a two-hundred day moving average price of $71.52. USANA Health Sciences, Inc. has a 1 year low of $58.30 and a 1 year high of $125.61.
USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, October 22nd. The company reported $1.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.22. The firm had revenue of $260.60 million for the quarter, compared to the consensus estimate of $256.22 million. USANA Health Sciences had a net margin of 9.38% and a return on equity of 27.60%. The business’s revenue for the quarter was down 12.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.24 EPS. On average, equities research analysts expect that USANA Health Sciences, Inc. will post 3.99 earnings per share for the current fiscal year.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Featured Article: What is the price-sales ratio?
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.